{"organizations": [], "uuid": "4d1851b3020f668e73e59662715c867d322296b3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/09/globe-newswire-adamas-announces-new-employment-inducement-grant.html", "country": "US", "domain_rank": 767, "title": "Adamas Announces New Employment Inducement Grant", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-10T01:26:00.000+02:00", "replies_count": 0, "uuid": "4d1851b3020f668e73e59662715c867d322296b3"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/09/globe-newswire-adamas-announces-new-employment-inducement-grant.html", "ord_in_thread": 0, "title": "Adamas Announces New Employment Inducement Grant", "locations": [], "entities": {"persons": [], "locations": [{"name": "emeryville", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}], "organizations": [{"name": "adamas pharmaceuticals, inc.", "sentiment": "neutral"}, {"name": "adamas pharmaceuticals, inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "EMERYVILLE, Calif., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees the option to purchase an aggregate of 42,250 shares of the company’s common stock, at a per share exercise price of $36.49, the closing trading price on February 7, 2018, and restricted stock units to acquire 8,625 shares of the company’s common stock. The stock option and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.\nAbout Adamas Pharmaceuticals, Inc.\nAdamas is using its deep understanding of time-dependent biology to redefine the treatment experience for patients suffering from chronic neurological diseases. The company is building upon the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease, with a pipeline of differentiated investigational programs, which includes ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial-onset seizures in patients with epilepsy. Adamas’ goal is to create and commercialize a new generation of neurological medicines intended to lessen the burden of disease on patients, caregivers and society. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com .\nContact: Ashleigh Barreto Director, Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. 510-450-3567 ir@adamaspharma.com\nSource:Adamas Pharmaceuticals, Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/78b294ca-f8a8-4bf4-bf30-8550f15be062", "https://www.globenewswire.com/Tracker?data=goIjn6Q2CXFPXr2PNwviK3QPYfBSUJTeThMFCJnxc5BO5iFMzqTfoq7SIPhG468bnnKE8zAFgK-eDsSWdaTwygAEbQELMheaQry9Ae_XhI0="], "published": "2018-02-10T01:26:00.000+02:00", "crawled": "2018-02-10T05:04:59.005+02:00", "highlightTitle": ""}